Geode Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-670,451
| Closed | -$11.9M | – | 4194 |
|
|
2018
Q3 | $11.9M | Buy |
670,451
+65,708
| +11% | +$1.13M | ﹤0.01% | 1795 |
|
|
2018
Q2 | $8.35M | Buy |
604,743
+219,961
| +57% | +$2.61M | ﹤0.01% | 2015 |
|
|
2018
Q1 | $3.5M | Buy |
384,782
+143,284
| +59% | +$790K | ﹤0.01% | 2464 |
|
|
2017
Q4 | $1.03M | Buy |
241,498
+32,603
| +16% | +$155K | ﹤0.01% | 3082 |
|
|
2017
Q3 | $294K | Hold |
208,895
| – | – | ﹤0.01% | 3534 |
|
|
2017
Q2 | $313K | Sell |
208,895
-64,862
| -24% | -$139K | ﹤0.01% | 3526 |
|
|
2017
Q1 | $703K | Buy |
273,757
+19,138
| +8% | +$44.3K | ﹤0.01% | 3175 |
|
|
2016
Q4 | $649K | Buy |
254,619
+8,754
| +4% | +$25.1K | ﹤0.01% | 3177 |
|
|
2016
Q3 | $759K | Buy |
245,865
+3,050
| +1% | +$9.51K | ﹤0.01% | 3084 |
|
|
2016
Q2 | $779K | Sell |
242,815
-2,862
| -1% | -$10.5K | ﹤0.01% | 3014 |
|
|
2016
Q1 | $761K | Buy |
245,677
+6,022
| +3% | +$19.7K | ﹤0.01% | 3021 |
|
|
2015
Q4 | $961K | Buy |
239,655
+3,674
| +2% | +$16.9K | ﹤0.01% | 2930 |
|
|
2015
Q3 | $1.08M | Buy |
235,981
+3,042
| +1% | +$15.9K | ﹤0.01% | 2828 |
|
|
2015
Q2 | $1.21M | Buy |
232,939
+29,480
| +14% | +$177K | ﹤0.01% | 2803 |
|
|
2015
Q1 | $1.27M | Buy |
203,459
+3,807
| +2% | +$22K | ﹤0.01% | 2728 |
|
|
2014
Q4 | $1.25M | Buy |
199,652
+255
| +0.1% | +$1.55K | ﹤0.01% | 2708 |
|
|
2014
Q3 | $1.21M | Buy |
199,397
+3,644
| +2% | +$24.9K | ﹤0.01% | 2673 |
|
|
2014
Q2 | $1.29M | Buy |
195,753
+20,144
| +11% | +$227K | ﹤0.01% | 2639 |
|
|
2014
Q1 | $4.18M | Buy |
175,609
+6,302
| +4% | +$91.4K | ﹤0.01% | 1885 |
|
|
2013
Q4 | $1.81M | Buy |
169,307
+24,802
| +17% | +$274K | ﹤0.01% | 2360 |
|
|
2013
Q3 | $1.93M | Buy |
144,505
+4,225
| +3% | +$66.8K | ﹤0.01% | 2195 |
|
|
2013
Q2 | $1.84M | Buy |
+140,280
| New | +$1.89M | ﹤0.01% | 2090 |
|
Other funds holding ECYT
Geode Capital Management's ECYT Position: Q4 2018 in Review
Geode Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 670,451 shares — an estimated $11.9M sold.
Geode Capital Management first reported a position in ECYT in Q2 2013 and held it in 22 quarters. The position peaked at $11.9M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.
- Geode Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
- Geode Capital Management sold 670,451 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $11.9M.
- Geode Capital Management first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 22 quarters.
- Geode Capital Management's Endocyte, Inc. Common Stock position peaked at $11.9M in Q3 2018.
- 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.
Based on Geode Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.